# Linagliptin in Schizophrenia Patients

> **NCT01943019** · PHASE1 · TERMINATED · sponsor: **Monash University** · enrollment: 1 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Linagliptin

## Key facts

- **NCT ID:** NCT01943019
- **Lead sponsor:** Monash University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2018-07
- **Final completion:** 2018-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Inability to obtain patients
- **Last updated:** 2018-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943019, "Linagliptin in Schizophrenia Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01943019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*